NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Probably not. I was, again, giving worse case percentage as to how many they reserved to in the US for after the enhancements. When I modeled it came out differently. But, it's still going to be a run to the finish. They did not enroll the Germany and Canada's combined 108-patient allotment until late 2014-summer 2015:

1)Germany 87-patient allotment: began screening (surgeries) in Q3 2014; enrollment is typically around 3 months later. It was a slow monthly accrual. Many other German sites were added in early 2015.

(Germany officially starting to screen in summer 2014 was confirmed on IZI annual report; and NW Bio confirmed due to trial enhancements, Europe enrollment would be a slow ramp up. This is the only country with lower WBC inclusion).

2) Canada 21-patients: joined the trial in Feb 2015, Q1 20015 screening began (surgery then); enrollment began 3 months later

As for the US and UK they were the original 141-patient Phase II trial open trial that turned into a 141-patient double-blinded trial with a crossover in 2008; that ultimately stopped in 2009-2010 due to funds, but eventually resumed in 2011 to 240-patient Phase II double-blinded trial, that included up to 48-patient pseudo arm (tertiary arm), and up-to 24-patients to over enroll to cover Lost to Follow Up patients. And ultimately it changed to a new Phase III study in 2012 once UK joined, approved for treatments (DC manufacturing; shipping etc). The main arm was only ever 240-patients. But, when Germany was added (in name only) in 2013, they used the 48+24, as a placeholder of pending Germany enrollment. And then they reported it enlarged when Germany was added, the numbers shifted, from 312-patients to 348-patient enrollment once they changed the Statistical Analysis Plan, that's when they started to screen. The 348-patients is only the main arm. And 240-patients is only the US and U.K. patients. Pseudos remain in a tertiary arm, capped at 32-patients. We do not know the LTFU allotment but I imagine it remains 10%.

And as far as the 240 enrollment:

3) UK-24 patients; I believe enrollment was complete before Germany began, in 2013-2014, probably over 4 quarters the most.

4) US-216 patients
2008 period:
11 patients were enrolled in 2008 period. (All others they mentioned in 2011 restarts are in the compassionate info arm)
SEC statements confirm only this count.
They were up to 49-patients in the US by August 2012, per the German protocol but imagine they ended the quarter above that.
I do think that they enrolled a decent percentage. Probably at least +190 patients before 2015:

It made an attempt to model the enrollment, so that folks get a sense where the events will mostly come from. I hope it is helpful. Because they were enrolling the pseudo arm, they would be trying to screen a little heavier during that period. I tried to created the best modeling of enrollment based on data that I accumulated and $ they had on hand. I did not model events only enrollment, and I tried to spread the enrollment evenly, per the region. My amateur attempt, take it with a grain of salt. Mostly you should see that if all these patients were on plain SOC that 248-PFS would have hit. Too many would have been enrolled early on. And then since Germany is enrolling lower WBC patients, those patient progression events should come in well before 15 month median high I could find for mMGMT status (WBC do correlate with survival). Hopefully that makes sense.

"NW Bio expects to complete enrollment in its phase III trial by Q1 or early Q2 of next year – an overall enrollment period of 14 or 15 calendar quarters, including both the 2008 period and the period since Q2 2011". --March 7, 2013

Q2 2008 screening -US  Phase II: 141-patient Double Blinded Placebo controlled crossover trial. 

Q3 2008: 11 patients
Q3 2011: 4 patients (15)
Q4 2011: 8 patients (23)
Q1 2012: 12 patients (35)
Q2 2012: 14 patients (49)
Q3 2012: 14 patient (63)
Q4 2012: 20 patients (83)
Q1 2013: 20 patients (103)
Q2 2013: 22 patients (125)
Q3 2013: 22 patients, UK screen (147)
Q4 2013: 22 patients (169)
-- 66 patient IA event, old SAP
Q1 2014: 18 patients (187)
Q2 2014:  18 patients (205)
-- Expanded access arm added on ClinicalRegister, pseudo arm likely closed. 
-- Fraunhofer IZI site clears, to enter the trial; 
Q3 2014: 14 Patients + Germany screens (219)
Q4 2014: 22 patients (241)
Q1 2015: 29 patients + Canada screens (270)
Q2 2015: 51 patients (321)
Q3 2015: 27 patients (lost some here) (348)
348 patient assumption

Remember their intention was to have the trial end by Q3, IMHO, as they were rushing to get it done before the Sept 2015 conference.

3.4. ESTIMATED ACCRUAL
It is estimated that accrual will average 0.5 – 2 participants per month per site, at
approximately 50 clinical sites participating in the study.

Full timeline data set, with lots of info added below to help model.

Anyone can mess around with the numbers, but essentially over 300 were enrolled before August 2015. ?
2007-2008 - Phase II 141-patient open label no placebo design -- 11 patient (estimate-open)
************
Q2 2008 screening -US Phase II: 141-patient open label becomes a 240-patient Double Blinded Placebo controlled crossover trial. 

Q3 2008 enrollment - US only - 11 patients 
(11 enrolled Q4 2008)

Q4 2008 no funds, site initiations only

2009-2010 Co. halts enrollment - FDA talks to Phase II 240-patient trial design, multi-national

Q1 2011 US reinitiates at sites 

Q2 2011 US screening resumes

Q3 2011 enrollment - US only +4
(4 enrolled Q3 2011)

Q4 2011 enrollment -US only +8
(8 enrolled Q4 2011)

Q1 2012 enrollment - US only +12
(12 enrolled Q1 2012)
--varying initiation stages to add U.K. and Germany 

Q2 2012 enrollment - US only, +14 patients
(14 enrolled Q2 2012)
-- official Phase III with pseudo cohort. 

Q3 2012 enrollment - US only +14 patient 
-- (49-patients in US overall by early August (include 11-patients in 2008)
--(then additional patients remainder of quarter)
(14 enrolled Q3 2012)

Q4 2012 enrollment - US only + 20 patients
(20 enrolled Q4 2012)
--faster US ramp; funds to enroll are in place)

Q1 2013 enrollment - US only +20 patients
(20 enrolled Q1 2013)

Q2 2013 enrollment - US only +22-patients
(22 enrolled Q2 2013)
---German manufacturing approved; 
-- PR about enrollment ramp (reported to be expected to be a total of 14-15 Qs). 

Q3 2013 enrollment - US +22-patients + UK begins screening.  (22 enrolled Q3 2013)
--Germany approved to join the Phase trial 
-- Enhanced DC TFF manufacturing patent approved.  

Q4 2013 enrollment - US +16 patients + UK +6-patients. (22 enrolled Q4 2013)
-- 66 patient IA event, old SAP 1st IA, no efficacy done; instead trial enhancements begin to change SAP; account for low WBC 

Q1 2014 enrollment - US +12-patients + UK +6 patients (18 enrolled Q1 2014)

Q2 2014  - US +12-patients + UK +6-patients 
(18 enrolled Q2 2014)
-- Expanded access arm added on ClinicalRegister, pseudo arm likely closed. 
-- Fraunhofer IZI site clears, to enter the trial; 
-- HE announcement. 

Q3 2014  US +8-patients + UK +6-patients  + Germany starts screening, August 2014 Fraunhofer IZI. 
(14 enrolled Q3 2014)
--Trial Enhancement Announced: New SAP
-- 348-patient trial 
-- PIMS

Q4 2014 enrollment - US +8-patients + Germany 14-patients slow ramp (22 enrolled Q4 2014) 

Q1 2015 enrollment - US +8-patients + German 21-patients Canada: screening (29 enrolled Q1 2015)

Q2 2015 enrollment - US +5-patients +Germany+ 34-patients + Canada 12+patients ramps down (51 enrolled Q2 2015)

Q3 2015 enrollment - Germany+18-patients  Canada 9-patient stragglers (27 enrolled Q3 2016)

348-patient max assumption

And here's the timeline, with company statements, [mine]: ?
SEC 10K 2008 Statement: The study was not blinded because there was no available approach for making a placebo that was indistinguishable from the DCVax®-L. Almost 50 patients were screened at 4 clinical sites. However, patients were reluctant to enroll in the study when faced with a 33% chance of being randomized into the control arm of the study under which they will receive standard of care alone. 

Following up on these results, in 2007-2008, the Company designed and began a 140-patient randomized, controlled Phase II trial but without a placebo and without blinding (which can only be achieved with a placebo that is indistinguishable from the new treatment being tested), as no placebo then existed for a living cell product like DCVax. Unfortunately, without a placebo and blinding, patients who were randomized to the control group in the trial knew that this was the case – and, not surprisingly, they tended to drop out of the trial. As a result, that 140-patient Phase II trial had to be stopped and a placebo had to be developed to enable blinding, so that patients would not know whether they were receiving DCVax or a placebo.?
We obtained a new FDA clearance and re-approvals by all the clinical sites, and commenced the new Phase II trial in early 2008. Unfortunately, we had only been underway for a short period when the economic crisis hit. We were able to keep the trial open, and continue treating the patients already enrolled in the trial, but we had to suspend new enrollment of additional patients into the trial. This suspension continued through the end of 2010, solely due to the severe economic downturn and resulting resource constraints.

June 2008 10Q (released on August 19, 2008): "to date only SIX patients have enrolled in the clinical trial, which is designed to include 240-patients. Given our lack of funding, it is unclear how quickly we will be able to increase enrollment, if at all. unsure if they could enroll more, financial constraints.”

Sept 2008 10Q (released on November 19, 2008): "to date only ELEVEN patients have enrolled in the clinical trial, which is designed to include 240-patients. Given our lack of funding, it is unclear how quickly we will be able to increase enrollment, if at all.”?
The study size has been increased from 141 to 240 patients and is designed to enable us to petition the FDA for accelerated approval if the study generates results similar to those achieved in earlier Phase I studies. In order to enable rapid enrollment, we are in the process of enrolling 45 to 50 additional clinical sites for this trial. As of January 1, 2009, thirteen sites are active and a further 31 sites are at various stages of the start-up process. We are engaged in discussions with the FDA concerning the study design and end points. Depending on trial results, we plan to seek product approval in both the U.S. and the European Union.?
SEC 10K 2008 Statement: Placebos to look indistinguishable from various kinds of pills have been made for decades, but creating a placebo to be indistinguishable from living cells in a vial (such as the living immune cells that comprise DCVax) was a new and difficult challenge. Not only must the placebo look indistinguishable from the DCVax visually, it must also not have any positive functional action of its own that would muddy the trial results. After considerable work, the Company succeeded in developing such placebo arrangements and re-designing the Phase II trial to accommodate them, including nearly doubling the number of patients (from 140 to 240 patients). The Company obtained a new FDA clearance and re-approvals by all the clinical sites, and commenced the new Phase II trial in early 2009.?
Dec 2009: Batch Manufacturing Patent, FDA cleared for clinical trials: ?
http://www.prnewswire.com/news-releases/northwest-biotherapeutics-receives-approval-of-us-patent-for-cost-saving-automation-of-high-concentration-dcvaxr-manufacturing-78507867.html
?
NWBO May 2011 Enrollment PR: "To date, 33 patients have already been enrolled in this ongoing 240-patient GBM brain cancer trial and its information arm an have been proceeding through the treatment regimen and follow-up.”?
SEC statement 2011: “The Company has already enrolled and treated 34 patients in this Phase II trial, including 22 patients in the trial arms and 12 patients in an information arm and the company has similar number of additional patients in various stages of the screening and enrollment process” 

[The May PR to me is clearly speaking about the NCT #, which began screening/recruiting 2007, as an open arm, became a double-blinded placebo control trial with compassionate use arm to accept fail screen patients (at least until the pseudo arm opened) 
Includes the 2011 SEC statement, of 33-patients +1 new patient (34 patients).  The 22 patients are in trial ARMS: Open Arm (prior to 2008) and Double-blinded Arm(Q2 2008, forward):Phase II 2017 Open Arm: 11 patients; Phase II Double-blinded: 11 patients (confirmed to be 11-patients by 11/19/2008); and then 12 patients in an information arm (CUA). ]
?
In Q1 of 2011, we began the process of resuming new enrollment – obtaining renewals of institutional review board or IRB approvals and other necessary steps. We resumed the enrollment activity in Q2 of 2011. At that time, the trial was only at a dozen sites and only in the US. During 2011, we expanded the trial to 25 sites across the US.
?
NW Bio has primarily been enrolling its Phase III trial since Q2 of 2011.  The Company undertook a limited period of enrollment in 2008, and then kept the trial going with the patients already enrolled, but suspended new enrollment due to resource constraints during the worst of the economic downturn, through the end of 2010. The Company began the process of reactivating clinical trial sites for new enrollment in Q1 2011, and resumed screening in Q2 of 2011.
?
In an amendment to the clinical trial protocol which became effective on May 3, 2012, the FDA, among other things, accepted the re-designation of this ongoing trial from a Phase II to a Phase III. In August 2012, the UK regulatory authority (the Medicines and Healthcare Products Regulatory Authority, or MHRA) also approved this trial to proceed in the UK as a Phase III trial.
?
http://www.nwbio.com/northwest-bio-provides-update-on-dcvax-l-brain-cancer-trial-2/?
[In May of 2012, the Company obtained permission to become a Phase III.  At that time they included a tertiary analyses cohort for pseudo-progression, of up-to 48 patients. The protocol was updated.   The main arm remained 240-patients, and the primary and secondary endpoints analyses for those patients did not change]?
PORTION BELOW Info from German Protocol comes out on enrollment [mine]:

Quote:The study 020221 is an ongoing Phase III study. By August 15, 2012 patients were enrolling in 41 clinics in the United States in the study and 84 GBM patients were included. Of these 84 patients in the Phase III study, 49 were randomized (2:1, active treatment against placebo), and 35 patients were enrolled in an open label arm of the study, specifically for patients with tumor progression that is faster. ?
[It only speaks of the Phase III main arm, and the compassionate use arm.  It seems that from May 2011 to August 2012, the double-blind portion of the trial has increase from 11-patients to 49-patients (11 enrolled/randomized in 2008; 38-patients enrolled since 2011; US 169-patients left to enroll); and the Compassionate use arm has grown from 12-patients to 35-patients, will eventually grow to 55 by end of Q4 2012, per 8-11-14 PR (which mean US main arm will likely grow by +25-patients by end of 2012); no mention of the status of 11-open-Phase II patients]
?
November 2011: $5.4 million financing?
http://www.nwbio.com/northwest-bio-announces-transactions-for-5-4-million-in-new-financing-2/

Our Current Phase III Clinical Trial:?
During 2012, the Phase III brain cancer trial was expanded to 42 sites in the US, and nearly 30 additional sites  were identified and in varying stages in the UK and Germany.
?
[The Company works for several years to add U.K. and Germany manufacturing. Germany to initially handle U.K. enrollment]: ?
April 2012: poised to proceed in Germany:

https://www.pipelinereview.com/index.php/2012042647762/Vaccines/After-13-Months-of-Complex-Processes-DCVax-L-Program-Poised-To-Proceed-In-Germany.html?
May 2012: $5.5 million German Gov't Grant ?
http://www.nwbio.com/northwest-bio-awarded-5-5-million-german-government-grant-2/?
Late May 2012:  Phase III Update: ?
http://www.nwbio.com/northwest-bio-provides-update-on-dcvax-l-brain-cancer-trial-2/
?
[They even refer to their recent announcements, one of which was the German grant to be used for manufacturing.  Poised to proceed in Germany but is clear that the process is not there yet] ?
July 2012: 18 month process to get certification in  Germany announced.  

http://www.nwbio.com/fraunhofer-izi-receives-official-certification-for-manufacturing-of-northwest-bios-dcvax-l-product/
?
August 2012: Expands WW production capacity ?
http://www.fiercebiotech.com/biotech/northwest-bio-expands-worldwide-production-capacity-for-dcvax®-l

December 2012: $13.8 million 
?
http://www.nwbio.com/northwest-biotherapeutics-to-ring-the-nasdaq-stock-market-opening-bell-2/
?
[NORTHWEST BIO ANNUAL REPORT SHOWS STRONG PROGRESS  - Very clear update on all programs, including HE.  ?
-- Having manufacturing processes for two products that have been accepted by regulators for clinical trials at the  Phase III (which processes must be the same as to be used for COMMERCIALIZATION) -- a significant milestone, especially for cellular therapy product. $32 million raised for the year (enrollment funds there to ramp up) ]?
http://www.nwbio.com/wp-content/uploads/2013/06/press2013.04.08.pdf?
March 2013: US Patent for Producing more potent D.C. (Europe would come a few months later) ?
http://www.nwbio.com/nw-bio-receives-u-s-patent-on-broad-processes-for-producing-more-potent-dendritic-cells/
  
March 2013: NW Bio provide guidance on trial enrollment 
?
http://www.nwbio.com/wp-content/uploads/2013/06/press2013.03.07.pdf
?
As of March 31, 2013, there are 43 clinical sites open and operating for the trial across the United States with more expected to become operational during 2013. 
?
[Enrollment ramping up in US]?
May 2013: NW Bio Fact Sheet:?
http://www.nwbio.com/wp-content/uploads/2013/06/NW-Bio-Leader-In-Immune-Therapy-One-Pager-May-2013-.pdf

May 2013: Initiates in Europe. Kings College site opens:?
http://www.nwbio.com/nw-bio-initiates-phase-iii-dcvax-l-brain-cancer-trial-in-europe-kings-college-hospital-in-the-uk-is-first-site-to-open-2/

August 2013:  $15 million up to ...
?
http://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-registered-direct-offering-218978671.html

Late Sept 2013: German cleared for entry.  
?
http://www.nwbio.com/german-regulator-authorizes-nw-bios-phase-iii-gbm-trial-to-open/?
"This rapid regulatory response represents the last step in a long approval process before one of the most rigorous regulators in the world. It enables NW Bio to proceed with its Phase III trial in Germany, where the Company plans to include more than 20 top German hospital centers. These German centers will be joining more than 55 clinical trial sites currently operating in the US, as well as sites in the UK, as part of NW Bio’s international 312-patient, double blind, randomized, placebo-controlled Phase III clinical trial of DCVax®-L for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Based upon the PEI’s approval, NW Bio will now proceed with the final administrative steps with the individual German hospital centers, in order for enrollment to begin."

Manufacturing of DCVax
 
We believe that our proprietary manufacturing process for DCVax products is a key to our favorable product economics, and we are positioning DCVax to be a potential front line therapy. We have spent more than a decade honing this manufacturing process.
 
We have pioneered a manufacturing model under which at least 3 years of treatments are produced in one large batch in each manufacturing cycle. In addition, we have implemented special cryopreservation methods which enable this multi-year quantity of product to be frozen, and kept frozen for years, while maintaining its potency.
 
Both of these technologies, the multi-year batch manufacturing and the cryopreservation, are essential elements of our manufacturing model and product economics. Together, they enable us to incur the high costs of manufacturing just one time, and then store the multi-year quantity of product, frozen, in single doses. This makes DCVax effectively an “off the shelf” product for the patient after the initial manufacturing, even though it is personalized, and we anticipate that this will enable the pricing of DCVax to be in line with modern, non-personalized cancer drugs. We also believe that both automation and economies of scale will further enhance the product economics.
 
Our manufacturing process has been taught to, and replicated at, Kings College in England and the Fraunhofer Institute in Germany, so that the same efficiencies and quality controls will be present for the DCVax produced both in Europe and the United States.?
Sept 2013: TFF Patent: 
?
http://www.nwbio.com/nw-bios-patent-portfolio-further-expanded-with-manufacturing-automation-patent/

Dec 2013: Robust balance sheet.  $25 million funding 

http://www.nwbio.com/wp-content/uploads/2013/12/NWBT-corp-overview-Dec-2013-12-10-13.pdf
?
December 2013: First Interim Analysis Trigged?
http://www.nwbio.com/first-interim-analysis-of-nw-bios-phase-iii-gbm-trial-triggered-by-reaching-required-number-of-events/
?
December 2013: Respond to Shareholder Inquires of Immunotherapy Sector Decline:
?
http://www.nwbio.com/nw-bio-responds-to-shareholder-inquiries-following-immune-therapy-sectors-recent-market-decline/?
April 2014 10K:?
https://www.sec.gov/Archives/edgar/data/1072379/000114420414020023/v371700_10k.htm

"In December 2013, we announced that the number of events required to trigger the first interim analysis of the Phase III clinical trial had been reached. This milestone is measured by "events," which are defined as either a tumor recurrence or a death.  With the current trial size, the pre-specified trigger number for the first interim analysis is 66 such events, comprising 60% of the 110 events required to reach the primary endpoint of the Phase III trial.  The interim analysis will be conducted by an independent Data Monitoring Committee, or DMC, with assistance from the independent clinical research organization, or CRO, managing the trial. In March 2014, we announced that the DMC has conducted a review of the safety data, and recommended that the trial continue as planned. As we also announced the DMC’s interim analysis of efficacy data remains outstanding. With the current trial size, a second interim analysis will occur when 88 events, comprising 80% of the total 110 events, have been reached." --SEC 10k 2013

[First IA: 66-patient primary events breached. In May the IA remains outstanding, but safety is a "continue".  Later we learn that instead of the DMC doing an efficacy in Dec 2013, the Company opted to forego, instead to focus on a 9-month regulatory process to amend the SAP begins; to add Germany to the trial (not one patient had been recruited yet!). I can't believe that at the time I thought there was legitimacy to SA "efficacy" halt article. That type of conjecture hurt their bottom line.  Clearly the company was still able to enroll in Germany at that point.]
?
April 2014:  $15 million ... up to $32 million
?
http://www.nwbio.com/nw-bio-announces-financing-of-up-to-32-million/
?
March 2014 Hospital Exception announced. Germany still not recruiting for Phase III: 
?
http://www.nwbio.com/nw-bio-announces-two-german-approvals-hospital-exemption-for-early-access-program-with-dcvax-l-and-eligibility-of-dcvax-l-for-reimbursement/
?
June 2014:  Germany joins DCVax-L Phase III OFFICIALLY.  The PR speaks about the 6-month process to add hospital sites.?
http://www.nwbio.com/dcvax-l-phase-iii-trial-initiated-in-germany/
?
August 2014: Information Arm: CUA?
http://www.nwbio.com/nw-bio-provides-update-about-phase-iii-dcvax-l-trial-for-gbm-and-information-arm-compassionate-use-case-patients/
?
August 2014: Phase III Trial Enhancements.  New SAP: ?
http://www.nwbio.com/nw-bio-obtains-approvals-for-enhancements-of-phase-iii-trial-of-dcvax-l-for-gbm-brain-cancer/?
"Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered.
Company Remains Blinded, With No Access to Trial Data At Any Time"

BETHESDA, Md., August 11, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, following a 9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing Phase III clinical trial of DCVax-L Glioblastoma multiforme (GBM) brain cancer.  The enhancements will allow the statistical analysis of trial results to take account of a major new variable which has been identified in GBM research since the Company’s Phase III trial began, and will lower the threshold for satisfying the primary endpoint of the trial." --8-11-14 PR

Sept 2014: UK PIM EAMS: ?
http://www.nwbio.com/nw-bios-cancer-vaccine-is-the-first-drug-to-be-designated-by-uk-authorities-as-a-promising-innovative-medicine-pim/?
October 2014: $11.5 million?
http://www.nwbio.com/nw-bio-announces-11-5-million-financing/?
October 2014:  Germany HE first patients. ?
http://www.nwbio.com/dcvax-l-hospital-exemption-program-now-under-way-in-germany/?
December 2014: $25 million Woodford  + $10 million mortgage?
http://www.fiercepharma.com/r-d/northwest-bio-gets-40m-more-for-controversial-brain-cancer-vaccine
?
Feb 2015: Canada joins Phase III-- two sites join and begin screening 
?
https://www.google.com/amp/seekingalpha.com/amp/news/2312466-northwest-bio-cleared-to-begin-dcvax-l-study-in-canada?client=safari?
April 2015: $40 million Woodford:?
http://www.fiercepharma.com/r-d/northwest-bio-gets-40m-more-for-controversial-brain-cancer-vaccine
?
April 2015: CUA data 

http://immuno-oncologynews.com/2015/04/13/northwest-biotherapeutics-reports-promising-survival-data-in-glioblastoma-multiforme-patients-treated-with-dcvax-l/

May 2015: $28.5 million portion closes
?
http://www.nwbio.com/nw-bio-closes-28-5-million-second-tranche-woodford-40-million-financing/

August 2015:  NW Bio confirms trial is on-going, but screen-halted:?
http://www.nwbio.com/nw-bio-confirms-phase-iii-trial-of-dcvax-l-for-gbm-brain-cancer-is-ongoing/?
October 2015: $30 million Woodford:

http://www.streetinsider.com/dr/news.php?id=10990384

December 2015: $12.6 million?
http://www.nwbio.com/nw-bio-announces-closing-of-registered-direct-offering-of-12-6-million/?
February 2016:  $10 million, but up to ...$27.6

http://www.nwbio.com/nw-bio-announces-registered-direct-offering-of-up-to-27-6-million-with-existing-institutional-investors/?
July 2016: $3.7 million:?
http://www.nwbio.com/nw-bio-announces-a-registered-direct-offering-of-3-7-million-with-new-institutional-investors/
?